CONMED Corporation reported its financial results for the second quarter of 2026, revealing a slight increase in net sales to $343.5 million, up from $342.3 million in the same period last year. For the first half of 2026, net sales totaled $660.5 million, a decrease from $663.6 million in the prior year. The company’s gross profit for the quarter was $197.5 million, resulting in a gross margin of 57.5%, an increase from 55.0% in the previous year. Net income for the quarter was $23.1 million, or $0.77 per diluted share, compared to $21.4 million, or $0.69 per diluted share, in the same quarter of 2025.

The company experienced a notable shift in its product lines, particularly with the exit from its gastroenterology offerings, which significantly impacted sales. Gastroenterology sales were $4.7 million in the second quarter of 2026, down from $25.3 million in the same quarter of 2025. In contrast, orthopedic surgery sales increased by 8.2% year-over-year, driven by growth in powered surgical instruments and sports medicine products. General surgery sales, however, decreased by 5.2%, primarily due to the exit from gastroenterology products.

Operationally, CONMED's total assets decreased to $2.3 billion as of June 30, 2026, down from $2.3 billion at the end of 2025. The company reported a current ratio of 1.48, indicating a solid liquidity position. The company’s employee headcount remained stable, with no significant changes reported. Additionally, CONMED's selling and administrative expenses rose to $145.6 million for the quarter, reflecting increased costs associated with operational optimization and advisory services.

Looking ahead, CONMED anticipates continued challenges from inflationary pressures and supply chain disruptions, which may affect its operational costs. The company has engaged a consulting firm to evaluate its manufacturing operations and is actively monitoring its spending. Despite these challenges, CONMED remains committed to its strategic initiatives, including the ongoing development of its orthopedic and general surgery product lines. The company expects to leverage its existing cash flow and available credit to meet its future capital requirements and continue its share repurchase program, which has already seen $43.7 million in stock repurchases this year.

About CONMED Corp

CONMED Corporation is a medical technology company that designs, manufactures, and distributes surgical devices and equipment for orthopedics, general surgery, gynecology, thoracic, and gastroenterology procedures. Its products include implants, minimally invasive surgical tools, power systems, and single-use consumables. Serving healthcare providers worldwide, the company emphasizes innovation, quality, and global expansion to deliver advanced surgical solutions and improve patient outcomes.

This description was generated via AI from an annual report. Updated about 1 year ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.

View the complete official filing on the SEC website.

Read on SEC.gov